September 30, 2021
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, September 2021

A focus on leukemia trials; an update regarding advanced practice providers; two important topics related to patient communication
September 30, 2021

Now Enrolling: Phase II of EA9152 for Acute Lymphoblastic Leukemia

This phase Ib/II study is testing the effects and safety of venetoclax in combination with liposomal vincristinein patients with B-ALL or T-ALL
September 30, 2021

NCI-MATCH Eliminates the Need for a Formal Referral Letter from the Laboratories

Removing one of several steps will help speed the process for identifying patients who may be eligible to enroll for treatment in NCI-MATCH
September 30, 2021
Jill Feldman and Kristin Ito Headshots

A New Guide Encourages the Use of Language that is Respectful of Patients, Free of Stigma, Inclusive, and Equitable

A new Language Guide provides guidelines on best practices with common phrases to use during presentations at medical conferences and within submitted abstracts
September 30, 2021
Envelope and paper

Should Participants Know the Arm to Which They Were Assigned in a Randomized Clinical Trial?

The ethical imperative is that we must not treat the patient as a mere subject but as a participant partner, who therefore has rights to information about the trial to which they contributed
September 30, 2021
Patient and doctor talking

Trial Spotlight: Selina Luger on the PrE0905 Study for FLT3 Mutated Acute Myeloid Leukemia

This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
September 30, 2021
News in Brief

News in Brief, September 2021

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more